Sankey It
Loading...
Pfizer Inc. FY2025 income statement | Sankey It
Sankey It · PFE
Pfizer Inc. FY2025 income statement
USD · fiscal year ended 2025-12-31
FY2025
FY2024
FY2023
FY2022
FY2021
Quarterly
Annual
comfortable
compact
Hide amounts
Export
Fullscreen
Pfizer Inc. FY2025 income statement
Flow diagram with 9 nodes and 8 flows for Pfizer Inc. FY2025 income statement. Values: Biopharma Segment US$61.2B, Segment Reporting, Reconciling Item, Corporate Nonsegment US$1.4B, Revenue US$62.6B, Cost of Revenue US$18.6B, Gross Profit US$44B, Operating Expenses US$28.6B, Operating Income US$15.4B, Other Expense US$7.9B, Net Income US$7.8B.
Biopharma Segment
US$61.2B
-2% Y/Y
98% of revenue
Segment Reporting, Reconciling Item, Corporate Nonsegment
US$1.4B
2% of revenue
Revenue
US$62.6B
-2% Y/Y
Cost of Revenue
(US$18.6B)
-15% Y/Y
30% of revenue
Gross Profit
US$44B
+5% Y/Y
70% margin
Operating Expenses
(US$28.6B)
+13% Y/Y
46% of revenue
Operating Income
US$15.4B
-6% Y/Y
25% margin
Other Expense
(US$7.9B)
-6% Y/Y
13% of revenue
Net Income
US$7.8B
-3% Y/Y
12% margin
Net / profit
Inputs
Tax / cost
Copy link
Share on X
Open full screen